Conditions and diseases
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Technology appraisal guidance [TA509]
07 March 2018
Tools and resources
Information for the public
Review and download supporting evidence. Includes the full guideline if available.